Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Durata Therapeutics Inc.

Division of Allergan PLC
www.duratatherapeutics.com

Latest From Durata Therapeutics Inc.

Takeda/Shire Deal Stands Fifth Largest In Biopharma M&A

The $62.4bn price tag for Takeda’s acquisition of Shire is topped globally only by the Pfizer take-outs of Warner-Lambert and Wyeth, the merger that created GlaxoSmithKline, and Actavis’ purchase of Allergan.

Japan Europe

AMR Roundtable Part 1: Incentives Spur Antimicrobial Investments, But More Needed

Scrip spoke with the CEOs of antibiotic firm Zavante and antifungal specialist Amplyx as well as a BARDA official who oversees antibiotic funding programs during a roundtable discussion at BIO about what's needed to boost antimicrobial drug development. Topics addressed in this part 1 of the discussion include company funding strategies, impact of the CARB-X program, and unique opportunities and challenges for antifungals.

Business Strategies Infectious Diseases

Iterum Therapeutics Focused On First Oral Penem

Emerging Company Profile: Iterum Therapeutics is developing a Phase III-ready penem antibiotic, sulopenem, which could be the first in its class to be administered orally. It’s the second foray into setting up an anti-infectives-focused company by a team of experienced biotech executives and entrepreneurs that previously took Durata’s dalbavancin through clinical development.

StartUps and SMEs Financing

Medicare Add-On Payments For Praxbind, Andexanet Under Consideration

Although few drugs have ever gotten the new technology designation, the two antidotes for excessive bleeding caused by anticoagulant treatments seem to have a good chance of being awarded added payments by CMS.

BioPharmaceutical United States
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
  • Therapeutic Areas
  • Infectious & Viral Diseases
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Allergan PLC
  • Senior Management
  • Corey Fishman, COO, CFO
    Michael Dunne, MD, CMO
    John P Shannon, Chief Commercial Officer
    John J White, VP, Bus. Dev.
  • Contact Info
  • Durata Therapeutics Inc.
    Phone: (312) 219-7000
    200 S. Wacker Dr.
    Ste. 2550
    Chicago, IL 60606
    USA
Advertisement
Advertisement
UsernamePublicRestriction

Register